ARTICLE | Clinical News
E-3810: Phase I started
October 4, 2010 7:00 AM UTC
EOS began an open-label, dose-escalation, European Phase I trial to evaluate once-daily oral E-3810 in patients with advanced solid tumors. EOS has worldwide rights to E-3810 from Advenchen for oncolo...